|
In response to the shortage of inhalation solution products with the preferred brand name Xopenex, HHSC removed the non-preferred status from the generic levalbuterol inhalation solution products on the preferred drug list (PDL) effective Oct. 31, 2023. Providers can now prescribe the generic levalbuterol inhalation solution without requiring a PDL prior authorization, allowing clients to continue accessing necessary medication. A list of generic levalbuterol products is available online.
Reminders:
|
